-
公开(公告)号：US20120129768A1
公开(公告)日：2012-05-24
申请号：US13388056
申请日：2010-07-29
申请人： Yali Wang , Aifeng Lü , Changan Sun , Hengli Yuan
发明人： Yali Wang , Aifeng Lü , Changan Sun , Hengli Yuan
IPC分类号： A61K38/26 , A61P3/10 , A61P3/04 , C07K14/605
CPC分类号： C07K14/605 , A61K38/00
摘要： This invention discloses GLP-1 analogues and their pharmaceutical salts, wherein the GLP-1 analogue comprises an amino acid sequence of general formula (I), wherein Lys represents a modified lysine with a lipophilic acid. The GLP-1 analogues provided by this invention have the function of human GLP-1, and a longer half-life in vivo compared with the human GLP-1. Uses of such compounds and compositions include treating non-insulin-dependent diabetes, insulin-dependent diabetes, and obesity. (I) X1-X2-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12- X13-X14-Glu-X16-X17-Ala-X19-X20-X21-Phe-Ile-X24- Trp-Leu-X27-X28-X29-X30-X31-X32-X33-X34-X35-X36- X37-X38-X39-Lys
摘要翻译： 本发明公开了GLP-1类似物及其药物盐，其中GLP-1类似物包含通式（I）的氨基酸序列，其中Lys表示具有亲脂性酸的经修饰的赖氨酸。 本发明提供的GLP-1类似物具有人GLP-1的功能，与人GLP-1相比体内的半衰期更长。 这些化合物和组合物的用途包括治疗非胰岛素依赖性糖尿病，胰岛素依赖型糖尿病和肥胖症。 （I）X1-X2-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12-X13-X14-Glu-X16-X17-Ala-X19-X20-X21-Phe-Ile-X24 - Trp-Leu-X27-X28-X29-X30-X31-X32-X33-X34-X35-X36-X37-X38-X39-Lys
-
公开(公告)号：US08614182B2
公开(公告)日：2013-12-24
申请号：US13362593
申请日：2012-01-31
申请人： Yali Wang , Aifeng Lü , Changan Sun , Hengli Yuan
发明人： Yali Wang , Aifeng Lü , Changan Sun , Hengli Yuan
CPC分类号： A61K38/26 , C07K14/605 , G01N33/566
摘要： This invention discloses GLP-1 analogues and their pharmaceutical salts, wherein the GLP-1 analogue comprises an amino acid sequence of general formula (I), wherein Lys represents a modified lysine with a lipophilic acid. The GLP-1 analogues provided by this invention have the function of human GLP-1, and a longer half-life in vivo compared with the human GLP-1. Uses of such compounds and compositions include treating non-insulin-dependent diabetes, insulin-dependent diabetes, and obesity. X1-X2-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12-X13-X14-Glu-X16-X17-Ala-X19-X20-X21-Phe-Ile-X24-Trp-Leu-X27-X28-X29-X30-X31-X32-X33-X34-X35-X36-X37-X38-X39-Lys Formula (I)—SEQ ID NO: 238
摘要翻译： 本发明公开了GLP-1类似物及其药物盐，其中GLP-1类似物包含通式（I）的氨基酸序列，其中Lys表示具有亲脂性酸的经修饰的赖氨酸。 本发明提供的GLP-1类似物具有人GLP-1的功能，与人GLP-1相比体内的半衰期更长。 这些化合物和组合物的用途包括治疗非胰岛素依赖性糖尿病，胰岛素依赖型糖尿病和肥胖症。 X1-X2-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12-X13-X14-Glu-X16-X17-Ala-X19-X20-X21-Phe-Ile-X24-Trp- Leu-X27-X28-X29-X30-X31-X32-X33-X34-X35-X36-X37-X38-X39-LysFormula（I）-SEQ ID NO：238
-
公开(公告)号：US20120196798A1
公开(公告)日：2012-08-02
申请号：US13362593
申请日：2012-01-31
申请人： Yali Wang , Aifeng Lü , Changan Sun , Hengli Yuan
发明人： Yali Wang , Aifeng Lü , Changan Sun , Hengli Yuan
IPC分类号： A61K38/26 , A61P3/10 , A61P3/04 , C07K14/605
CPC分类号： A61K38/26 , C07K14/605 , G01N33/566
摘要： This invention discloses GLP-1 analogues and their pharmaceutical salts, wherein the GLP-1 analogue comprises an amino acid sequence of general formula (I), wherein Lys represents a modified lysine with a lipophilic acid. The GLP-1 analogues provided by this invention have the function of human GLP-1, and a longer half-life in vivo compared with the human GLP-1. Uses of such compounds and compositions include treating non-insulin-dependent diabetes, insulin-dependent diabetes, and obesity. (I) X1-X2-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12- X13-X14-Glu-X16-X17-Ala-X19-X20-X21-Phe-Ile-X24-Trp- Leu-X27-X28-X29-X30-X31-X32-X33-X34-X35-X36-X37-X38-X39- Lys
摘要翻译： 本发明公开了GLP-1类似物及其药物盐，其中GLP-1类似物包含通式（I）的氨基酸序列，其中Lys表示具有亲脂性酸的经修饰的赖氨酸。 本发明提供的GLP-1类似物具有人GLP-1的功能，与人GLP-1相比体内的半衰期更长。 这些化合物和组合物的用途包括治疗非胰岛素依赖性糖尿病，胰岛素依赖型糖尿病和肥胖症。 （I）X1-X2-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12-X13-X14-Glu-X16-X17-Ala-X19-X20-X21-Phe-Ile-X24 -Trp-Leu-X27-X28-X29-X30-X31-X32-X33-X34-X35-X36-X37-X38-X39-Lys
-
-
搜索结果
3 条记录 (耗时 0.018 秒)